Please wait while the formulary information is being retrieved.
PORTRAZZA (NECITUMUMAB)
- Squamous cell carcinoma of lung
800 mg/50 mL (16 mg/mL) intravenous solution
- Infuse 800 mg over 60 minute(s) by intravenous route on days 1 and 8 of each 3 week treatment cycle
Squamous cell carcinoma of lung
- Infuse 800 mg over 60 minute(s) by intravenous route on days 1 and 8 of each 3 week treatment cycle
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Pregnancy
- Thromboembolic disorder
Severe
Moderate
- None
PORTRAZZA (NECITUMUMAB)
- Squamous cell carcinoma of lung
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Hypophosphatemia
- Maculopapular rash
- Acneiform eruption
- Diarrhea
- Erythema
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Hemoptysis
- Pulmonary thromboembolism
- Venous thrombosis
- Acne vulgaris
- Conjunctivitis
- Dry skin
- Dysphagia
- Headache disorder
- Mouth irritation
- Muscle spasm
- Paronychia
- Pharyngitis
- Phlebitis after infusion
- Pruritus of skin
- Skin fissure
- Stomatitis
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Induration of skin
- Thrombophlebitis
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Necitumumab
No safety and efficacy established in pediatrics.
- 1 Day – 18 Years
- No safety and efficacy established in pediatrics.
Necitumumab
- Severity Level:
D
- Additional Notes: Based on drug pharmacology potential for dev tox
Contraindicated
Necitumumab
Potential for serious adverse outcomes, manufacturer does not recommend
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Potential for serious adverse outcomes, manufacturer does not recommend |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Rarely, heart problems (cardiopulmonary arrest) or sudden death have occurred in people treated with necitumumab. Before starting treatment with this medication, tell your doctor if you have a history of heart disease (such as heart failure, irregular heartbeat, previous heart attack). Get medical help right away if you develop chest/jaw/left arm pain, shortness of breath, or unusual sweating. Your doctor will order certain blood tests (such as magnesium, calcium, and potassium) during and after your treatment to monitor and help decrease your risk for heart problems.
| Squamous cell carcinoma of lung | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| 0-9 | A-Z |
|---|---|
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
Formulary Reference Tool